文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

米诺环素预防危重症患者谵妄:一项随机对照试验

Prophylactic Minocycline for Delirium in Critically Ill Patients: A Randomized Controlled Trial.
PubMed 文献 · Chest · 2023-12-01
一句话结论在4个ICU的随机对照试验中,米诺环素100 mg每日两次使28天内或ICU出院前谵妄发生率从35%降至20%(P=.043),但研究提前终止且样本量小,作者认为需进一步研究确认。

该研究为随机、安慰剂对照、双盲试验,在4个ICU纳入≥18岁危重症患者,随机接受米诺环素100 mg每日两次或安慰剂,主要终点为28天内或ICU出院前谵妄发生率。共160例随机,1例安慰剂组死亡未纳入分析,最终分析159例(米诺环素组84例,安慰剂组75例);COVID-19疫情后决定提前停止纳入。米诺环素组谵妄发生率20%(17例)vs 安慰剂组35%(26例),差异小但显著(P=.043);其他谵妄相关结局无改变;意外发现医院死亡率显著下降(39% vs 23%,P=.029);仅C反应蛋白组×时间交互显著(F=4.09,P=.045)。作者认为该较小样本研究提示米诺环素可能对谵妄发生率有正面影响,需进一步研究确认其作为危重症患者预防措施获益。

要点

  • 在4个ICU的随机对照试验中,米诺环素100 mg每日两次使28天内或ICU出院前谵妄发生率从安慰剂组35%(26例)降至20%(17例),P=.043。
  • 米诺环素未改变其他谵妄相关结局(包括ICU期间谵妄天数、无谵妄/昏迷天数等)。
  • 意外发现医院死亡率米诺环素组23% vs 安慰剂组39%,P=.029。
  • 仅血浆C反应蛋白水平在米诺环素治疗后显著下降(组×时间 F=4.09,P=.045)。
  • 研究因COVID-19疫情提前停止纳入,最终分析159例,作者认为需进一步研究确认获益。

适用人群与场景

  • 年龄18岁及以上的危重症患者,入住4个ICU之一。

处置流程与药物剂量

  • 米诺环素100 mg,每日两次,与安慰剂对照;主要终点为28天内或ICU出院前谵妄发生率。

研究设计与关键结果

  • 研究设计:随机、安慰剂对照、双盲试验,在4个ICU进行;共160例随机,1例安慰剂组患者在治疗前死亡,最终分析159例(米诺环素组n=84,安慰剂组n=75);COVID-19疫情后决定提前停止纳入。
  • 主要终点:28天内或ICU出院前谵妄发生率米诺环素组20%(17例)vs 安慰剂组35%(26例),P=.043。
  • 其他谵妄相关结局:米诺环素治疗未改变任何其他谵妄相关结局。
  • 医院死亡率:米诺环素组23% vs 安慰剂组39%,P=.029。
  • 生物标志物:在所有分析的生物标志物中,仅血浆C反应蛋白水平在米诺环素治疗后显著下降(组内随时间 F=0.75,P=.78;组×时间 F=4.09,P=.045)。

证据类型、等级与局限

  • 证据类型:随机、安慰剂对照、双盲试验(ClinicalTrials.gov注册号NCT04219735)。
  • 局限:研究样本量较小(最终分析159例);因COVID-19疫情提前停止纳入;作者指出需进一步研究确认该药作为危重症患者预防措施的获益。

对床旁实践的改变

  • 作者认为,该较小样本研究提示米诺环素可能对谵妄发生率有正面影响,需进一步研究确认其作为危重症患者预防措施的获益。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Delirium is a potentially severe form of acute encephalopathy. Minocycline has neuroprotective effects in animal models of neurologic diseases; however, data from human studies remain scarce.

RESEARCH QUESTION: Does the neuroprotective effect of minocycline prevent delirium occurrence in critically ill patients?

STUDY DESIGN AND METHODS: This study was a randomized, placebo-controlled, double-anonymized trial conducted in four ICUs. Patients aged 18 years or older were eligible and randomized to receive minocycline (100 mg, twice daily) or placebo. The primary outcome was delirium incidence within 28 days or before ICU discharge. Secondary outcomes included days in delirium during ICU stay, delirium/coma-free days, length of mechanical ventilation, ICU length of stay, ICU mortality, and hospital mortality. The kinetics of various inflammatory (IL-1β, IL-6, IL-10, and C-reactive protein) and brain-related biomarkers (brain-derived neurotrophic factor and S100B) were used as exploratory outcomes.

RESULTS: A total of 160 patients were randomized, but one patient in the placebo group died before treatment; thus the data from 159 patients were analyzed (minocycline, n = 84; placebo, n = 75). After the COVID-19 pandemic it was decided to stop patient inclusion early. There was a small but significant decrease in delirium incidence: 17 patients (20%) in the minocycline arm compared with 26 patients (35%) in the placebo arm (P = .043). No other delirium-related outcomes were modified by minocycline treatment. Unexpectedly, there was a significant decrease in hospital mortality (39% vs. 23%; P = .029). Among all analyzed biomarkers, only plasma levels of C-reactive protein decreased significantly after minocycline treatment (F = 0.75, P = .78, within time; F = 4.09, P = .045, group × time).

INTERPRETATION: Our findings in this rather small study signal a possible positive effect of minocycline on delirium incidence. Further studies are needed to confirm the benefits of this drug as a preventive measure in critically ill patients.

CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov; No.: NCT04219735; URL: www.

CLINICALTRIALS: gov.

来源:Chest,查看原文。版权归原作者所有。

参考来源

  1. Dal-Pizzol F, Coelho A, Simon CS, et al. Prophylactic Minocycline for Delirium in Critically Ill Patients: A Randomized Controlled Trial. Chest. 2023. PMID: 38043911. doi:10.1016/j.chest.2023.11.041

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。